Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Glenmark: Growth across businesses - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Glenmark: Growth across businesses

Oct 30, 2012

Glenmark has announced its 2QFY13 results. The company has reported 19% YoY growth in sales and a 180% YoY increase in net profits. Here is our analysis of the results.

Performance summary
  • Topline grows by 19% YoY during the quarter led by growth in both its speciality and generics businesses.
  • Operating margins improve marginally by 0.3% leading to a 20% YoY growth in operating profits.
  • Bottomline increases by 180% YoY during 2QFY13. However, on excluding the extraordinary item during 2QFY12, bottomline declines by 16% YoY due to higher tax expenses.

Financial Performance : A snapshot
(Rs m) 2QFY12 2QFY13 Change 1HFY12 1HFY13 Change
Net sales 10,554 12,552 18.9% 19,237 22,955 19.3%
Expenditure 8,301 9,842 18.6% 14,017 18,596 32.7%
Operating profit (EBDITA) 2,253 2,710 20.3% 5,220 4,359 -16.5%
EBDITA margin (%) 21.3% 21.6%   27.1% 19.0%  
Other income (35) 67   91 98 8.0%
Interest (net) 333 413 23.9% 750 815 8.6%
Depreciation 247 321 29.8% 510 595 16.7%
Profit before tax 1,637 2,044 24.8% 4,050 3,047 -24.8%
Exceptional Item 1,316 -   1,316 -  
Tax (238) 477   81 695 758.7%
Profit after tax/(loss) 559 1,567 180.2% 2,653 2,352 -11.3%
Net profit margin (%) 5.3% 12.5%   13.8% 10.2%  
No. of shares (m)         270.0  
Diluted earnings per share (Rs)         15.9  
Price to earnings ratio (x)*         24.8  
*based on trailing 12 months earnings

What has driven performance in 2QFY13?
  • Glenmark's topline grew by 19% YoY during the quarter led by growth in both its specialty and generics businesses. However excluding the licensing income from 2QFY12, the topline witnessed healthy growth of 34% YoY.

  • In the generics business, the US business recorded a growth of 44% YoY, and in constant currency terms growth was at 20%. A new competitor has entered the Malarone market, due to which the company witnessed higher price erosion. Glenmark has 43 products awaiting approval of which 19 are Para IVs. EU generics witnessed robust growth of 109%, on the back of new launches. Latin America too showed healthy growth of 29%. Large part of the growth was driven by all regions except Brazil. Further, the company expects its Latam segment to break even at EBITDA levels in FY13 and Central Europe to break even at EBITDA levels in FY14.

    Consolidated Business Snapshot
    (Rs m) 2QFY12 2QFY13 Change 1HFY12 1HFY13 Change
    Generics Business
    US 3,001 4,307 43.5% 5,512 8,231 49.3%
    Europe 185 389 109.6% 361 721 99.8%
    Latin America 41 54 29.9% 70 93 32.5%
    API 763 1,035 35.6% 1,409 2,039 44.8%
    Total Generics (i) 3,990 5,784 45.0% 7,352 11,084 50.8%
    Specialty Business            
    India 2,539 3,440 35.5% 4,793 6,238 30.2%
    RoW 1,479 1,941 31.2% 2,526 3,289 30.2%
    Latin America 738 937 26.9% 1,330 1,567 17.8%
    Europe 378 379 0.5% 593 649 9.5%
    Total Specialty Business (ii) 5,134 6,697 30.5% 9,242 11,744 27.1%
    Out Licensing Income (iii) 1,184     2,297 -  
    Others (iv) 246 71 -71.3% 347 128 -63.0%
    Total (i)+(ii)+(iii)+(iv) 10,554 12,552 18.9% 19,237 22,955 19.3%

  • In the Specialty segment, India witnessed robust growth of 30% vs. industry growth of 12.6%. Glenmark has increased its market share in Derma, Cardiac, Respiratory, Anti Infective, Gynecology and Pain. Importantly, the company does not see higher impact on its revenues due to pricing policy, as large part of its drugs does not fall in the NLEM list. As per management, even if cost plus pricing methodology is adopted, Glenmark's revenues will not get impacted by more than Rs 60-70 m. The other regions too witnessed healthy growth of 25%.
  • On the R&D front, the company incurred capex of Rs 700 m for Crofelemer drug. The USFDA has scheduled PDUFA (Prescription drug user fee act) for this drug in Jan 2013. This is when USFDA will declare the outcome for a particular drug; whether it is accepted or rejected. Over and above, the company is awaiting various results of its ongoing trials on various drugs in the next 12-18 months. Glenmark will also out license few of these drugs, irrespective of trials' outcome.

  • Operating margins improved marginally by 0.3% leading to a 20% YoY growth in operating profits. Further, Glenmark incurred MTM forex gain of Rs 150 m; excluding this, margins witnessed a marginal dip. This was due to higher R&D expenses which were at 8.6% of total sales vs. 6% in 2QFY13. The company has guided for a similar run rate of around 8% for 2HFY13.

  • Bottomline increased by 180% YoY during 2QFY13. However, on excluding the extraordinary item during 2QFY12, bottomline declined by 16% YoY due to higher tax expenses. For the full year, Glenmark expects tax rate to be in range of 17%-18% on back of the Sikkim unit becoming operational.

What to expect?
At the current price of Rs 430, the stock is trading at a price to earnings multiple of 11.6 times our estimated FY15 earnings. Going forward, the key growth drivers for the company will be the US, Latin America and ROW markets. In US especially, its focus on a niche product portfolio will augur well for the company and The Indian business is expected to show good performance, on back of increased market share. We have also seen improvement on the balance sheet side with its working capital cycle improving and the debt reducing. The company is expecting trial data for its R&D pipeline in next 12-18 months and is also looking for outlicensing partners for its pipeline. Due to the company's strong performance in 1HFY13, we have upgraded our estimates for the next three years and we have a 'Buy' view on the stock.

To Read the Full Story, Subscribe or Sign In
To Read the Full Story, Subscribe or Sign In

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms


Mar 20, 2019 (Close)


  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks